Indian stocks: Visit www.stage2stocks.com →

Minerva Neurosciences, Inc

Stage 4 · Declining · week 14

As of Oct 22, 2026, Minerva Neurosciences is in Stage 4, the downtrend phase, now in week 14 (since Jul 17, 2026). It closed at $2.40, 70.3% below its 52-week high and below its 200-day average, which is falling.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. More about the company

$2.40
-1.23% today
$115M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NERV early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 14w
S4 42w
S2 38w
S4 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 5w → S3 9w → S4 6w → S1 5w → S2 4w → S4 14w → S1 11w → S4 42w → S1 10w → S2 38w → S3 9w → S4 14w current
Total tracked: 166 weeks across 12 stage runs.

NERV among Biotechnology399th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…399NERVStage 4 · wk 1418−31.2%
vs 52W High
-70.3%
$2.32 lo$8.07 hi
70.3% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 14
1w13w26w
Week 14, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-51.7%
200 DMA: $4.97 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.63x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-31.2%
3M
-40.6%
6M
-64.9%
YTD
-38.8%
1Y
-62.6%
Scan Membership
Breakout Watch
Latest: 2024-02-07
7 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 14 · Vol 0.63x
2026-10-21S4
Wk 14 · Vol 0.48x
2026-10-20S4
Wk 14 · Vol 1.03x
2026-10-19S4
Wk 14 · Vol 0.62x
2026-10-16S4
Wk 13 · Vol 0.44x
2026-10-15S4
Wk 13 · Vol 0.83x
2026-10-14S4
Wk 13 · Vol 1.34x
2026-10-13S4
Wk 13 · Vol 0.99x
2026-10-12S4
Wk 13 · Vol 0.45x
2026-10-09S4
Wk 12 · Vol 1.04x
2026-10-08S4
Wk 12 · Vol 0.77x
2026-10-07S4
Wk 12 · Vol 0.57x
Moving averages & range
50 DMA
$3.76
200 DMA
$4.97
52W High
$8.07
52W Low
$2.32
5D Low
$2.32
Resistance levels (recent highs)
20d High
$3.43
60d High
$5.43
120d High
$6.33
250d High
$8.07
Next resistance
+42.9%
to 20d High
Dividend Yield
0.00%
P/B -0.5

Minerva Neurosciences: quick answers

What stage is Minerva Neurosciences in?

As of Oct 22, 2026, Minerva Neurosciences (NERV) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 17, 2026 and is in week 14. What the four stages mean

Is Minerva Neurosciences in an uptrend?

No. Minerva Neurosciences is in a Stage 4 downtrend. It trades 51.7% below its 200-day average, which is falling.

How far is Minerva Neurosciences from its 52-week high?

Minerva Neurosciences closed at $2.40 on Oct 22, 2026, 70.3% below its 52-week high of $8.07. Its 52-week low is $2.32.

How has Minerva Neurosciences performed over the past year?

As of Oct 22, 2026, Minerva Neurosciences is down 62.6% over the past year and down 38.8% so far in 2026.

Which sector and industry is Minerva Neurosciences in?

Minerva Neurosciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.